Amphastar Pharmaceuticals, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
Business Address 11570 SIXTH STREET, RANCHO CUCAMONGA, CA, 91730
Mailing Address 11570 SIXTH STREET, RANCHO CUCAMONGA, CA, 91730
Phone 909-980-9484
Fiscal Year End 1231
EIN 330702205
Financial Overview
FY2024 FY
$731.97M
Revenue
$159.52M
Net Income
$151.61M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | January 12, 2026 | View on SEC |
| 4 Insider stock transaction report | December 18, 2025 | View on SEC |
| 4 Insider stock transaction report | December 15, 2025 | View on SEC |
| 4 Insider stock transaction report | November 25, 2025 | View on SEC |
| 4 Insider stock transaction report | November 17, 2025 | View on SEC |
| 8-K Current report of material events | November 6, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 6, 2025 | View on SEC |
| 4 Insider stock transaction report | November 5, 2025 | View on SEC |
| 8-K Current report of material events | October 24, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | October 17, 2025 | View on SEC |
Insider Trading
SELL 3 insiders
4 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.